Your session is about to expire
← Back to Search
Intraocular Lens
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
N/A
Waitlist Available
Led By Thomas H Newsom, MD
Research Sponsored by Newsom Eye & Laser Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 and 3 months postoperative
Awards & highlights
No Placebo-Only Group
Summary
To evaluate visual outcomes and quality of vision following bilateral implantation of the Clareon PanOptix intraocular lens (IOL) targeted for emmetropia.
Eligible Conditions
- Pseudoaphakia
- Cataract
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 and 3 months postoperative
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 and 3 months postoperative
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Manifest refraction
Satisfaction questionnaire
Visual disturbances questionnaire
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: The Clareon™ PanOptix™ Trifocal (toric and non-toric models)Experimental Treatment1 Intervention
Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
The Clareon™ PanOptix™ Trifocal (toric and non-toric models)
2022
N/A
~40
Find a Location
Who is running the clinical trial?
SengiUNKNOWN
25 Previous Clinical Trials
1,981 Total Patients Enrolled
Newsom Eye & Laser CenterLead Sponsor
1 Previous Clinical Trials
35 Total Patients Enrolled
Thomas H Newsom, MDPrincipal InvestigatorNewsom Eye & Laser Center